Replies to post #43407 on Cytogenix (fka CYGX)

[marcusaurelius]

Well, you are entitled to interpret any post in whatever matter you like. If you feel I am being argumentative, then so be it.
However, I would hope that you would not single out my argumentativeness from that of numerous others who chronically post highly opinionated, character defaming, factually incorrect material that they seem to have made up entire. Or those whose seem to be gratified by taking essentially positive news and somehow using it as a stick to beat the company with. These are my opinions on what I have seen on this board; if some find these opinions helpful, I'm delighted. If some find them not helpful, that is their perogative.
I believe I have been consistent in my opinions about Cytogenix. IMHO, the science, which I know a great deal about, is rock solid (as are the scientists). I believe this augurs well for the future of the company. There are, as you are aware, substantial hurdles to the development of any new technology, synDNA not excepted, and the path to success in biotech is rarely if ever linear. The company is dealing with this, and with the fact that to date they do not have any peer-reviewed publications, which IMHO, is an absolute non-negotiable requirement for developing a sufficiently high profile where it counts. Let's face it, as I think you know, anybody can claim anything whatsoever, and big pharma, who sees literally dozens of such claims on a daily basis, has a right to be skeptical. But, the Catch-22 is that peer reviewed publications in respectable journals take time---you cannot rush them out the door, because they will be thrown back at you through the window.
However, none of this should be taken as a comment on the business direction of the company. Here, there are and have been, again IMHO, serious deficiencies, and I have clearly stated this repeatedly ad nauseum. I believe, and you are entitled to disagree, that much, but certainly not all, of these difficulties were related to the recently departed Gang of 2. Other problems have been exacerbated by the intrinsic nature of the company's science and of the field in which they are working. As far as the financials are concerned, this is an area that, even had I the very latest and best information, I would never discuss publicly.
Nevertheless, what I cannot countenance are the defamations, libels and sheer fantasies (with a conspiratorial edge) that appear here. I cannot silence the fantasists, but on the other hand, they cannot silence me. C'est la vie, but what I can guarantee is that the future, as it always does, will look nothing like anyone's predictions. Have a nice day, MA.